NAMSA, a company specializing in medical device testing, clinical research, and regulatory consulting, as completed the acquisition of the Early Development medical device testing business of Labcorp.

Thanks to the deal, NAMSA will assume the U.S. portfolio of services of Labcorp’s Early Development medical device business, including biocompatibility testing, microbiological testing, analytical testing, and preclinical research. The acquisition bolsters NAMSA’s position as a comprehensive innovation partner for end-to-end medical device development, enabling clients to access expanded expertise and streamlined solutions across the product lifecycle.

“This acquisition is a perfect fit for NAMSA—we serve 3,000+ medtech companies globally in these specific areas of testing and preclinical research,” said NAMSA CEO Brian Smith. “I am confident we will be able to provide Labcorp’s medical device clients with a smooth transition combined with the same high level of expertise and customer service current NAMSA clients have come to expect from us.”

NAMSA offers device testing, preclinical and clinical services, and regulatory consulting to medtech companies across the world. The company has facilities in the U.S., Europe, and Asia.

Future testing and preclinical project’s for Labcorp’s Early Development medical device clients will be done at NAMSA facilities in Ohio, Minnesota, Georgia, and California.

“The sale of our Early Development medical device testing business to NAMSA allows Labcorp to focus on core areas of preclinical drug development and chemical testing,” said Brian Caveney, M.D., EVP and president, Early Development Research Laboratories, Labcorp. “We are pleased NAMSA will continue providing leading expertise to clients in this space and are committed to a seamless transition.”

Early last year, NAMSA acquired the U.S. medical device testing operations of WuXi AppTec, a global company that provides a broad portfolio of R&D and manufacturing services for the pharmaceutical and life science industries.